Major companies moved to terminate or reprioritize assets after disappointing data. Johnson & Johnson halted its IL‑4/IL‑31 candidate JNJ‑95475939 following an interim futility analysis in atopic dermatitis; Genmab dropped the PD‑L1×4‑1BB bispecific acasunlimab. Ultragenyx announced plans for significant cost cutting after a pair of phase 3 failures in brittle bone disease. The decisions follow internal reviews and interim analyses and will reshape R&D priorities and near-term budgets at the affected firms.